Vaccine Adjuvant Incorporation Strategy Dictates Peptide Amphiphile Micelle Immunostimulatory Capacity

Current vaccine research has shifted from traditional vaccines (i.e., whole-killed or live-attenuated) to subunit vaccines (i.e., protein, peptide, or DNA) as the latter is much safer due to delivering only the bioactive components necessary to produce a desirable immune response. Unfortunately, sub...

Full description

Saved in:
Bibliographic Details
Published inThe AAPS journal Vol. 20; no. 4; p. 73
Main Authors Zhang, Rui, Kramer, Jake S., Smith, Josiah D., Allen, Brittany N., Leeper, Caitlin N., Li, Xiaolei, Morton, Logan D., Gallazzi, Fabio, Ulery, Bret D.
Format Journal Article
LanguageEnglish
Published Cham Springer International Publishing 01.07.2018
Subjects
Biochemistry
Biomedical and Life Sciences
Biomedicine
Biotechnology
Pharmacology/Toxicology
Pharmacy
Research Article
Theme: Pioneering Pharmaceutical Science by Emerging Investigators
Adjuvant
Peptide amphiphile micelles
Co-localization
Subunit vaccines
Online AccessGet full text

Cover

More Information
Summary:Current vaccine research has shifted from traditional vaccines (i.e., whole-killed or live-attenuated) to subunit vaccines (i.e., protein, peptide, or DNA) as the latter is much safer due to delivering only the bioactive components necessary to produce a desirable immune response. Unfortunately, subunit vaccines are very weak immunogens requiring delivery vehicles and the addition of immunostimulatory molecules termed adjuvants to convey protective immunity. An interesting type of delivery vehicle is peptide amphiphile micelles (PAMs), unique biomaterials where the vaccine is part of the nanomaterial itself. Due to the modularity of PAMs, they can be readily modified to deliver both vaccine antigens and adjuvants within a singular construct. Through the co-delivery of a model antigenic epitope (Ovalbumin 319–340 —OVA BT ) and a known molecular adjuvant (e.g., 2,3-dipalmitoyl-S-glyceryl cysteine—Pam 2 C), greater insight into the mechanisms by which PAMs can exert immunostimulatory effects was gained. It was found that specific combinations of antigen and adjuvant can significantly alter vaccine immunogenicity both in vitro and in vivo . These results inform fundamental design rules that can be leveraged to fabricate optimal PAM-based vaccine formulations for future disease-specific applications. Graphical Abstract
ISSN:1550-7416
1550-7416
DOI:10.1208/s12248-018-0233-6